TEPMETKO® (Tepotinib)

February 4, 2021February 4, 2021 RR FDA Approvals

The FDA on February 3, 2021 granted accelerated approval to TEPMETKO® for adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) harboring Mesenchymal-Epithelial Transition (MET) exon 14 skipping alterations. TEPMETKO® is a product of EMD Serono Inc.